Cathepsin B deficiency ameliorates liver lipid deposition, inflammatory cell infiltration, and fibrosis after diet-induced nonalcoholic steatohepatitis.
暂无分享,去创建一个
[1] A. Gastaldelli,et al. Crosstalk between adipose tissue insulin resistance and liver macrophages in Non Alcoholic Fatty Liver Disease. , 2019, Journal of hepatology.
[2] P. Libby,et al. Differential Roles of Cysteinyl Cathepsins in TGF-β Signaling and Tissue Fibrosis , 2019, iScience.
[3] T. Murohara,et al. Cathepsin S Deficiency Mitigated Chronic Stress–Related Neointimal Hyperplasia in Mice , 2019, Journal of the American Heart Association.
[4] P. Libby,et al. Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials , 2018, Nature Reviews Cardiology.
[5] Michael Charlton,et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.
[6] Huimin Wu,et al. Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease , 2017, Scientific Reports.
[7] R. Schwabe,et al. Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis. , 2016, Cell metabolism.
[8] D. Erion,et al. Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice. , 2016, Endocrinology.
[9] Marko Novinec,et al. Human cathepsin L, a papain‐like collagenase without proline specificity , 2015, The FEBS journal.
[10] M. Tomizawa,et al. Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. , 2014, Biomedical reports.
[11] S. Marchand-Adam,et al. Regulation of TGF-β1-driven Differentiation of Human Lung Fibroblasts , 2014, The Journal of Biological Chemistry.
[12] S. Hazen,et al. OxNASH Score Correlates with Histologic Features and Severity of Nonalcoholic Fatty Liver Disease , 2011, Digestive Diseases and Sciences.
[13] I. Bergheim,et al. In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD) , 2013, International journal of molecular sciences.
[14] F. Eren,et al. Linking Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: From Bedside to Bench and Back , 2013 .
[15] Zheng Zhang,et al. Liver fibrosis: mechanisms of immune-mediated liver injury , 2011, Cellular and Molecular Immunology.
[16] Guido Gerken,et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. , 2012, Journal of hepatology.
[17] A. Moles,et al. Cathepsin B Overexpression Due to Acid Sphingomyelinase Ablation Promotes Liver Fibrosis in Niemann-Pick Disease* , 2011, The Journal of Biological Chemistry.
[18] S. Bischoff,et al. Role of tumor necrosis factor α (TNFα) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. , 2011, The Journal of nutritional biochemistry.
[19] I. Leclercq,et al. Animal models for the study of hepatic fibrosis. , 2011, Best practice & research. Clinical gastroenterology.
[20] J. González‐Gallego,et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C , 2011, Gut.
[21] K. Moore,et al. Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. , 2010, Gastroenterology.
[22] J. Tschopp,et al. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? , 2010, Nature Reviews Immunology.
[23] S. Bischoff,et al. Toll‐like receptor 4 is involved in the development of fructose‐induced hepatic steatosis in mice , 2009, Hepatology.
[24] S. Erickson. Nonalcoholic fatty liver disease The author's work is supported by a Merit Award from the Department of Veterans Affairs and by DK-072187 from the National Institutes of Health. Published, JLR Papers in Press, December 12, 2008. , 2009, Journal of Lipid Research.
[25] A. Moles,et al. Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential , 2009, Hepatology.
[26] X. Su,et al. Cellular fatty acid uptake: a pathway under construction , 2009, Trends in Endocrinology & Metabolism.
[27] Z. Younossi,et al. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. , 2008, Cleveland Clinic journal of medicine.
[28] C. McClain,et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. , 2008, Journal of hepatology.
[29] Natalie J Torok,et al. Nonalcoholic steatohepatitis and the metabolic syndrome. , 2008, Metabolic syndrome and related disorders.
[30] J. Delgado. Evolving trends in nonalcoholic fatty liver disease. , 2008, European journal of internal medicine.
[31] R. Rector,et al. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. , 2008, World journal of gastroenterology.
[32] P. Portincasa,et al. Non-alcoholic fatty liver disease in the metabolic syndrome. , 2007, Current pharmaceutical design.
[33] Giulio Gabbiani,et al. The myofibroblast: one function, multiple origins. , 2007, The American journal of pathology.
[34] Christoph Peters,et al. Cathepsin L Deficiency Reduces Diet-Induced Atherosclerosis in Low-Density Lipoprotein Receptor-Knockout Mice , 2007, Circulation.
[35] N. Abumrad,et al. Role of CD36 in membrane transport and utilization of long-chain fatty acids by different tissues , 2001, Journal of Molecular Neuroscience.
[36] E. J. Lee,et al. PPARgamma activation induces CD36 expression and stimulates foam cell like changes in rVSMCs. , 2006, Prostaglandins & other lipid mediators.
[37] Jeanne M Clark,et al. The Epidemiology of Nonalcoholic Fatty Liver Disease in Adults , 2006, Journal of clinical gastroenterology.
[38] G. Link,et al. Fructose-Induced Fatty Liver Disease: Hepatic Effects of Blood Pressure and Plasma Triglyceride Reduction , 2005, Hypertension.
[39] M. Bogyo,et al. Regulation of Collagenase Activities of Human Cathepsins by Glycosaminoglycans* , 2004, Journal of Biological Chemistry.
[40] G. Gores,et al. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. , 2003, The Journal of clinical investigation.
[41] E. Brunt,et al. Pathology of nonalcoholic steatohepatitis. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.
[42] B. Gelb,et al. Collagenase Activity of Cathepsin K Depends on Complex Formation with Chondroitin Sulfate* , 2002, The Journal of Biological Chemistry.
[43] G. Gores,et al. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. , 2000, The Journal of clinical investigation.
[44] W. Fiers,et al. Cathepsin B-mediated activation of the proinflammatory caspase-11. , 1998, Biochemical and biophysical research communications.
[45] N. Gebbia,et al. Lysosomal cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications. , 1997, Oncology.
[46] N. Gebbia,et al. Cathepsin D Serum Mass Concentrations in Patients with Hepatocellular Carcinoma and/or Liver Cirrhosis , 1996, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.
[47] A. C. Webb,et al. Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. , 1994, The Journal of biological chemistry.
[48] H. Kawasaki,et al. Collagenolytic cathepsin B and L activity in experimental fibrotic liver and human liver. , 1992, Research communications in chemical pathology and pharmacology.